SALT LAKE CITY, Aug. 19, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN) ("Perseon" or the "Company"), today announced the launch of INSPIRE 2017, a new campaign which is dedicated to the growth and direction of the company over the next three years, particularly in the area of lung cancer, a disease where MicroThermX is better suited to treatment than other energy ablation products due to the system's 915 MHz frequency and synchronous wave alignment technology.
INSPIRE 2017 will reinforce the use of energy ablation in an industry where awareness is low, provide economic outcomes highlighting the impact of energy ablation, and continue to provide education to doctors and patients on the benefits of MicroThermX ablation technology.
In an effort to expand data supporting MicroThermX, Perseon is initiating five clinical studies in over 110 subjects as well as two non-clinical studies.
Additionally, the company is working to provide economic outcomes data via two separate initiatives. The first phase will be conducted with the assistance of current MicroThermX users and shared at an upcoming industry conference in early 2016. The second phase will provide a large scale economic model that will support the use of energy ablation.
"Perseon is generating momentum for energy ablation in an effort to raise the awareness of a technology that should be much more widely known and regarded due to its clinical outcomes and economic benefits," said Clint E. Carnell, President and CEO of Perseon. "INSPIRE 2017 is an extension of the company's ongoing engagement with the healthcare community, including physicians, healthcare systems, and patients, who are the reason we strive to continue developing cutting edge, life-saving technologies that fight cancer."
MicroThermX is an energy ablation system, which uses targeted microwave energy to treat cancer by ablating (burning) soft tissue with heat alone. Current treatment sites include cancers of the liver, kidney, bone, and lung. Perseon will continue to expand treatment targets to include other potential organs such as the pancreas, uterus, abdomen, and breast.
About Perseon Corporation
Perseon Corporation, formerly BSD Medical Corporation, invests its resources in fighting humanity's worst disease – cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy ablation solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.
Perseon's energy ablation system, MicroThermX, has been developed as a stand-alone therapy that employs precision-guided microwave energy to ablate (burn) and destroy soft tissue. Perseon has developed extensive intellectual property and has established distribution in the United States, Europe and Asia.
Treatment sites include tumor ablation of the liver, kidney, brain, bone, lung, and other soft-tissue locations.
Statements contained in this press release that are not historical facts, including statements relating to our focus on microwave ablation to create stockholder value and pursuit of our strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
CONTACT: Jennifer R. Hoglin Vice President of Global Marketing Phone: (801) 972-5555 Email: firstname.lastname@example.org